About
Veravas develops diagnostic tests that detect biomarkers in blood and other samples with high precision. Their VeraBIND technology cleans samples by removing interferences, which leads to more accurate results in early disease detection. This approach supports measured steps toward health optimization by providing clear data on conditions like Alzheimer's tau pathology.
The company offers products such as the VeraBIND Tau assay, a blood test for Alzheimer's-related tau pathology, along with assays for Borrelia antibodies and tTG antibodies linked to celiac disease. These tools enable clinicians and researchers to identify issues early through non-invasive methods. Veravas focuses on sustainable diagnostic solutions that integrate into clinical workflows.
By transforming complex samples into cleaner ones, VeraBIND supports personalized health strategies based on precise biomarker readings. This positions Veravas to aid in proactive monitoring for neurological and other conditions.
Longevity Contribution
- VeraBIND technology removes interferences from plasma samples to enable accurate detection of low-abundance biomarkers like hyperphosphorylated tau.
- First blood-based test (VeraBIND Tau) specifically for detecting active tau pathology in Alzheimer's, unlike tests focused only on amyloid.
- Provides semi-quantitative scoring for clear yes/no results on pathology presence, reducing diagnostic ambiguity.
- Modular platform applicable to multiple assays including Borrelia and tTG antibodies for broader disease screening.